Cargando…

Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment

While topical corticosteroid (TCS) treatment is widely used for many skin diseases, it can trigger adverse side effects, and some of such effects can last for a long time after stopping the treatment. However, molecular changes induced by TCS treatment remain largely unexplored, although transient c...

Descripción completa

Detalles Bibliográficos
Autores principales: Choi, Yongsu, Takasugi, Masaki, Takemura, Kazuaki, Yoshida, Yuya, Kamiya, Tomonori, Adachi, Jun, Tsuruta, Daisuke, Ohtani, Naoko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775701/
https://www.ncbi.nlm.nih.gov/pubmed/36551249
http://dx.doi.org/10.3390/biom12121822
_version_ 1784855708271902720
author Choi, Yongsu
Takasugi, Masaki
Takemura, Kazuaki
Yoshida, Yuya
Kamiya, Tomonori
Adachi, Jun
Tsuruta, Daisuke
Ohtani, Naoko
author_facet Choi, Yongsu
Takasugi, Masaki
Takemura, Kazuaki
Yoshida, Yuya
Kamiya, Tomonori
Adachi, Jun
Tsuruta, Daisuke
Ohtani, Naoko
author_sort Choi, Yongsu
collection PubMed
description While topical corticosteroid (TCS) treatment is widely used for many skin diseases, it can trigger adverse side effects, and some of such effects can last for a long time after stopping the treatment. However, molecular changes induced by TCS treatment remain largely unexplored, although transient changes in histology and some major ECM components have been documented. Here, we investigated transcriptomic and proteomic changes induced by fluocinolone acetonide (FA) treatment in the mouse skin by conducting RNA-Seq and quantitative proteomics. Chronic FA treatment affected the expression of 4229 genes, where downregulated genes were involved in cell-cycle progression and ECM organization, and upregulated genes were involved in lipid metabolism. The effects of FA on transcriptome and histology of the skin largely returned to normal by two weeks after the treatment. Only a fraction of transcriptomic changes were reflected by proteomic changes, and the expression of 46 proteins was affected one day after chronic FA treatment. A comparable number of proteins were differentially expressed between control and FA-treated skin samples even at 15 and 30 days after stopping chronic FA treatment. Interestingly, proteins affected during and after chronic FA treatment were largely different. Our results provide fundamental information of molecular changes induced by FA treatment in the skin.
format Online
Article
Text
id pubmed-9775701
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97757012022-12-23 Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment Choi, Yongsu Takasugi, Masaki Takemura, Kazuaki Yoshida, Yuya Kamiya, Tomonori Adachi, Jun Tsuruta, Daisuke Ohtani, Naoko Biomolecules Article While topical corticosteroid (TCS) treatment is widely used for many skin diseases, it can trigger adverse side effects, and some of such effects can last for a long time after stopping the treatment. However, molecular changes induced by TCS treatment remain largely unexplored, although transient changes in histology and some major ECM components have been documented. Here, we investigated transcriptomic and proteomic changes induced by fluocinolone acetonide (FA) treatment in the mouse skin by conducting RNA-Seq and quantitative proteomics. Chronic FA treatment affected the expression of 4229 genes, where downregulated genes were involved in cell-cycle progression and ECM organization, and upregulated genes were involved in lipid metabolism. The effects of FA on transcriptome and histology of the skin largely returned to normal by two weeks after the treatment. Only a fraction of transcriptomic changes were reflected by proteomic changes, and the expression of 46 proteins was affected one day after chronic FA treatment. A comparable number of proteins were differentially expressed between control and FA-treated skin samples even at 15 and 30 days after stopping chronic FA treatment. Interestingly, proteins affected during and after chronic FA treatment were largely different. Our results provide fundamental information of molecular changes induced by FA treatment in the skin. MDPI 2022-12-06 /pmc/articles/PMC9775701/ /pubmed/36551249 http://dx.doi.org/10.3390/biom12121822 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Choi, Yongsu
Takasugi, Masaki
Takemura, Kazuaki
Yoshida, Yuya
Kamiya, Tomonori
Adachi, Jun
Tsuruta, Daisuke
Ohtani, Naoko
Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment
title Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment
title_full Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment
title_fullStr Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment
title_full_unstemmed Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment
title_short Characterization of Transcriptomic and Proteomic Changes in the Skin after Chronic Fluocinolone Acetonide Treatment
title_sort characterization of transcriptomic and proteomic changes in the skin after chronic fluocinolone acetonide treatment
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9775701/
https://www.ncbi.nlm.nih.gov/pubmed/36551249
http://dx.doi.org/10.3390/biom12121822
work_keys_str_mv AT choiyongsu characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment
AT takasugimasaki characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment
AT takemurakazuaki characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment
AT yoshidayuya characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment
AT kamiyatomonori characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment
AT adachijun characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment
AT tsurutadaisuke characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment
AT ohtaninaoko characterizationoftranscriptomicandproteomicchangesintheskinafterchronicfluocinoloneacetonidetreatment